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1. Introduction 
Pediatric acute lymphoblastic leukemia (ALL) is the most prevalent cancer in children. 
Today in developed countries around 80% of children with ALL can achieve 10 year 
survival. This great improvement in treatment outcomes for pediatric ALL is due to several 
important advances which have taken place since the 1960s,  including intensive 
induction/consolidation chemotherapy regimens,  risk-adapted therapy,  central nervous 
system prophylaxis,  aggressive supportive care (especially prophylaxis and treatment for 
infections) and minimal residual disease detection. Rapid progress in molecular biology has 
helped to select patients with specific poor prognostic genetic factors and sensitive 
monitoring of minimal residual disease has also contributed significantly to the 
management of pediatric ALL. However,  patients with extremely poor prognostic factors or 
delayed response to chemotherapy still experience disease relapse. Hematopoietic stem cell 
transplantation (HSCT),  mainly using allogenic stem cells (bone marrow,  peripheral blood 
or umbilical cord blood stem cells),  has been proven to be an effective alternative and to 
ensure long-term survival for patients with relapsed ALL or with extremely poor prognostic 
factors.  However,  there are complications such as severe infections and chronic graft-
versus-host disease (GVHD) that may be occurred. Recent advances in the development of 
new formulations of existing drugs,  targeted therapy and immunotherapy provide new 
options in treatment of patients with refractory disease and promise to further improve of 
the cure rates of pediatric ALL. 
2. Characteristics of pediatric acute lymphoblastic leukemia 
Leukemia is the most common malignancy in the pediatric population,  comprising 30% of 
malignant tumors in children (Chiang et al., 2010; Young and Miller, 1975). The most 
prevalent subtypes of pediatric leukemia are acute lymphoblastic leukemia (75~80%) and 
acute myelogenous leukemia (15~17%)(Feltbower et al., 2009).   
Common presenting symptoms of pediatric ALL include fever, pallor, hepatosplenomegaly, 
lymph node swelling and hemorrhage. Bone pain or arthralgia is sometimes reported. The 
diagnosis of pediatric ALL is based on examination of cell morphology, cytochemistry and 
immunochemical analysis of bone marrow aspirates. Pediatric ALL can be classified 
according to different characteristics: L1, L2 or L3 by morphology, and B-cell, T-cell, co-
expression of myeloid antigens or mixed type by immunophenotyping. Risk-adapted 
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therapy is the main strategy for pediatric ALL treatment and has achieved a 5-year event-
free survival rate of approximately 80% in recent years. 
3. Chemotherapy 
3.1 Basic treatment principles 
Treatment for pediatric ALL comprises two major components: multi-drug combination 
chemotherapy and intrathecal (IT) chemotherapy for central nervous system (CNS) 
prophylaxis. Modern protocols have a number of design elements in common including a 
remission induction phase, a consolidation/intensification phase, and a CNS treatment and 
continuation (maintenance) phase, with or without delayed intensification (Provan et al., 
2009). Multi-drug combination chemotherapy has been the mainstay of ALL management 
since the late 1960s and a major survival improvement was achieved when 8-week, 8-drug 
induction/consolidation regimens followed by maintenance therapy were introduced in the 
1970s. CNS prophylaxis therapy with IT chemotherapy alone or with cranial radiation was 
added to the treatment regimen after the induction phase and markedly reduced CNS 
involvement in leukemia from around 80% to 4~6%(Evans et al., 1970; Moghrabi et al., 2007; 
Pui, C.H. et al., 2009). Following consolidation treatment, maintenance chemotherapy is 
initiated and continued for 2~3 years.   
3.2 Evolution of regimens 
During the late 1960s and early 1970s, patients with pediatric ALL were treated with a three-
drug regimen (vincristine, prednisolone and asparaginase) to induce remission, CNS 
prophylaxis therapy with weekly IT methotrexate (MTX) and cranial radiation was 
performed during the intensification phase followed by continuation treatment consisting of 
daily oral mercaptopurine, weekly oral MTX and monthly pulses of prednisolone and 
vincristine (Schrappe et al., 2010). Later, an early multiple agent induction/consolidation 
regimen was developed by Dr Riehm (Riehm et al., 1977). This comprised 8-drug induction 
chemotherapy for 9 weeks (prednisolone, daunorubicin, vincristine, asparaginase, 
methotrexate, mercaptopurine, cyclophosphamide and cytarabine) and 4 cycles of high-dose 
methotrexate (HDMTX) with daily oral mercaptopurine for 8 weeks. This improved the cure 
rate to over 50%. The high remission rate was thought to be related to the intensified 
remission induction phase. The requirement for precise and robust supportive care in 
specialized hospitals undertaken by experienced medical staff was emphasized in order to 
control treatment-related complications (Riehm et al., 1977; Schrappe et al., 2010). This 
approach remains at the core of modern pediatric ALL regimens.  
Risk-adapted therapy stratified by age and initial white blood cell count was demonstrated 
to increase the remission rate in poor risk groups and to decrease acute and chronic 
toxicities in good risk groups (Henze et al., 1981). The system of risk classification based on 
age and white blood cell count was extended by addition of other important prognostic 
factors for pediatric ALL (Table 1). The application of risk-adapted therapy in clinical trials 
has resulted in a steady improvement in the outcome of pediatric ALL, with a current 
overall survival rate of around 80% in developed countries (Jeha and Pui, 2009). The 
significance of early response to induction treatment , as measured by reduction in 
peripheral blood blast cells, was proposed in 1987 and used as an indicator to divide 
patients into different risk groups (Riehm et al., 1987). Since then, many more prognostic 
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factors have been identified and integrated into risk-classification systems. With the 
advances in genome-wide screening techniques, pharmacogenomic studies, and 
development of molecular therapeutics an era of more refined personalized therapy is 
anticipated (Pui, C.H., 2010). 
 
Risk 
group  
Age 
(y) 
Leukocyte 
count (/ul)
Immunophenotype Chromosome Genotype Early response 
to 
chemotherapy# 
Low  1-9 <50, 000 Precursor B-cell  Hyperdiploidy* TEL-AML1 Good 
High  <1 or 
≧10 
>50, 000 T-cell Hypodiploidy* MLL-AF4 
BCR-ABL 
Poor 
*hyperdiploidy: >50 chromosome; hypodiploidy: <44 chromosome 
#defined as MRD at the end of induction chemotherapy (good response: MRD<0.01%; poor response: 
MRD≧1%) 
Table 1. Prognostic factors used for risk classification in pediatric ALL (adapted from (Pui, 
C.H., 2010) with permission) 
National and international treatment groups have been established worldwide with the 
objective of improving the management of childhood ALL. The long-term results of recently 
completed clinical trials are listed in Table 2 (Conter et al., 2010; Gaynon et al., 2010; Liang et 
al., 2010; Mitchell et al., 2010; Moricke et al., 2010; Pui, C.H. et al., 2010). In Taiwan, the 
Taiwan Pediatric Oncology Group was formed in 1988 and marked progress in ALL 
treatment has been achieved with overall survival increasing from 59% during 1988~1995 to 
82% during 2003~2009.  
 
Study 
group 
Trial  Year Case number 10-year EFS 
(%) 
10-year OS 
(%) 
CCG CCG-1900 1996-2002 4464 72.6 82.1 
AIEOP AIEOP-ALL 
95 
1995-2000 1743 71.7 82.4 
BFM ALL-BFM 95 1995-2000 2169 78 85 
SJCRH Total 13B 1994-1998 247 80.1* 85.7* 
SJCRH Total 14 1998-1999 53 79.2 77.4 
SJCRH Total 15 2000-2007 498 85.6* 93.5* 
UK-
WPCL 
UKALL 97 1997-2002 1948 74 83 
TPOG TPOG-2002 2002-2007 788 77.4* 83.5* 
CCG: Children’s Cancer Group; AIEOP: Associazione Italiana di ematologia ed Oncologia Pediatrica; 
BFM: Berlin-Frankfurt-Munster ALL Study Group; SJCRH: St Jude Children’s Research Hospital; UK-
WPCL: UK Medical Research Council Working Party on Childhood Leukemia; TPOG: Taiwan Pediatric 
Oncology group; EFS: event-free survival; OS: overall survival ; *5-year EFS and OS 
Table 2. Treatment outcomes for selected pediatric ALL study groups 
3.3 Central nervous system treatment  
Early in the 1960s central nervous system(CNS) treatment was applied to the “total” therapy 
for pediatric ALL since it was found that better control of systemic leukemia was 
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accompanied by increased frequency of CNS involvement (Aur, R.J. and Pinkel, 1973; 
Simone, J.V., 1973). Radiation therapy of the CNS and IT MTX administration were the two 
main strategies for preventing CNS disease (Glidewell and Holland, 1973; Kim et al., 1972; 
Rosner and Grunwald, 1973; Simone, J. and Pinkel, 1973). Dosage and treatment modalities 
of CNS radiation were studied in an attempt to reduce neurotoxicities while maintaining 
effectiveness (Simpson et al., 1973). The St. Jude leukemia group compared cranial radiation 
with IT MTX and craniospinal irradiation in clinical trials and suggested that combined 
cranial radiation and IT MTX treatment was as effective as craniospinal irradiation with 
fewer toxicities (leukopenia and interruption of treatment)(Aur, R.J.A. et al., 1973). Since 
then, combined cranial irradiation and IT MTX have become the standard treatment for 
preventing CNS disease. However, further studies revealed that survivors of pediatric ALL 
who received high doses of cranial irradiation (over 25 Gy) or who were treated at a young 
age (younger than 2 years) suffered from significant long-term sequelae, such as defective 
cognitive function and secondary malignancy (Moe and Holen, 2000; Spiegler et al., 2006). 
Therefore, some study groups suggested that the dose of radiation be decreased to less than 
18 Gy (Henze et al., 1983) or that the extended IT MTX treatment be used as a replacement 
for cranial irradiation in low-risk patients (Conter et al., 1995). However, some treatment 
groups preferred to continue to employ cranial irradiation because of the poor prognosis 
with CNS leukemia (Gelber et al., 1993). After a lengthy debate regarding the role of cranial 
irradiation in pediatric ALL treatment, Pui CH et al. published their study results in this 
issue and suggested that ’with effective risk-adjusted chemotherapy, prophylactic cranial 
irradiation can be safely omitted from the treatment of childhood ALL’(Pui, C.H. et al., 
2009).  
4. Minimal residual disease 
Complete remission of ALL has been defined as blastic cells less than 5% of nucleated cells 
on bone marrow smear. Before the introduction of molecular methods or multicolor flow 
cytometry techniques, the percentage of blastic cells was measured by morphology, with a 
sensitivity of 1%. During the last twenty years, rapid progress in molecular biology has 
greatly improved the sensitivity of residual blastic cell detection, especially in the range 1% 
to 0.01%, which is designated minimal residual disease (MRD) (Campana and Pui, 1995; 
Neale et al., 1994). A new definition of remission was then established on the basis of 
immunologic or molecular response. A better clinical outcome is predicted in patients who 
achieve 'immunologic' or 'molecular' remission (ie leukemic involvement of <0.01% of 
nucleated bone marrow cells after initial intensive chemotherapy) compared with patients 
whose remission is defined solely by morphologic criteria (Coustan-Smith et al., 2000; Pui, 
C.H. and Campana, 2000). Among the various methods using immunologic or molecular 
characteristics of blastic cells as markers, the most promising are flow cytometric detection 
of aberrant immunophenotypes, and polymerase chain reaction analysis of clonal antigen-
receptor gene rearrangements or leukemia-specific fusion genes (Campana and Pui, 1995; 
Coustan-Smith et al., 1998; Ludwig et al., 1990; van Dongen et al., 1999). Taken together, 
almost all patients with pediatric ALL can be monitored for MRD during the course of 
treatment (Campana et al., 2001; Chen et al., 2001; Neale et al., 2004; Pui, C.H. and Campana, 
2000). Recent studies indicated that monitoring of MRD constituted an essential prognostic 
marker, and that detection of MRD, particularly at the end of induction and after treatment 
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completion, was significantly predictive for patient outcome (Katsibardi et al., 2010; Stow et 
al., 2010).  
5. The role of hemopoietic stem cell transplantation in pediatric acute 
lymphoblastic leukemia 
Hemopoietic stem cell transplantation was introduced for children with ALL in the 1970s. 
Along with the significant improvements in clinical outcome observed in patients receiving 
chemotherapy, HSCT became the treatment choice for relapsed cases and patients with poor 
prognostic factors (Gratwohl et al., 1990; Makipernaa et al., 1995; Uderzo et al., 1995). In 
early studies, 40 to 50% of relapsed patients achieved long remissions and were potentially 
cured by marrow transplantation. However, the effectiveness of the approach was 
diminished by the problems of acute and chronic GVHD, infection, and relapse(Johnson, 
1990; Moussalem et al., 1995; Pinkel, 1994; Wingard et al., 1990). Currently, HSCT is only 
considered in patients with extremely poor prognostic factors (for example, Philadelphia 
chromosome positive [PH+] ALL with poor response to induction therapy), with delayed 
response to chemotherapy (induction failure, MRD >1% on the end of remission date or 
MRD >0.01% prior to reinduction of chemotherapy) and in patients who experience early 
relapse (Arico et al., 2010; Burke et al., 2009; Davies and Mehta, 2010; Pulsipher et al., 2011).  
6. Recent advances in therapy and research in pediatric ALL 
Philadelphia chromosome-positive ALL has been found to be associated with a poor 
response to conventional chemotherapy and a high relapse rate, especially in patients older 
than 10 years (Arico et al., 2010). HSCT has been employed in patients with PH+ ALL in an 
attempt to improve long-term outcomes. In the early 2000s, BCR-ABL targeted strategies 
started to be incorporated into the treatment for PH+ ALL. Imatinib, a first generation 
tyrosine kinase inhibitor, showed its efficacy in improving the treatment outcome in 
PH+ALL with or without HSCT (Alvarado et al., 2007; Carpenter et al., 2007; Champagne et 
al., 2004; Fuster et al., 2007; Jones, L.K. and Saha, 2005). Given the marked improvement in 
treatment results achieved with combinations of a tyrosine kinase inhibitor (imatinib) and 
intensive chemotherapy, transplantation is not recommended for the first remission of 
children with PH+ ALL, unless the early response to treatment was poor (Barr, 2010; Gruber 
et al., 2009; Koo, 2011; Liu et al., 2009; Milone and Enrico, 2009; Ottmann and Pfeifer, 2009; 
Schultz et al., 2009).  Second generation tyrosine kinase inhibitors were developed because 
imatinib may induce specific resistance mainly due to ABL1 mutations. Dasatinib, a multi 
tyrosine kinase inhibitor targeted to BCR-ABL, SRC, C-KIT, PDGFR and ephrin A receptor 
kinase, and nilotinib, another BCR-ABL targeted agent similar to imatinib but with a higher 
affinity, are two novel agents with the potential to address PH+ALL resistance to imatinib 
(Alvarado et al., 2007; Aplenc et al., 2011; Kawaguchi et al., 2005; Kolb et al., 2008; Linger et 
al., 2009; Piccaluga et al., 2007; Porkka et al., 2008). 
Mixed lineage leukemia (MLL) rearrangements occur in 80% of infants and 5% of older 
children with ALL. MLL-rearranged ALL patients have poor treatment outcomes with 
conventional chemotherapy. FLT3 (FMS-like tyrosine kinase receptor-3) is one of the unique 
gene expression profiles in MLL-rearranged ALL. Eighteen percent of MLL-rearranged ALL 
harbored activating mutations of FLT3 with high expression levels (Armstrong et al., 2003; 
Brown et al., 2005). In vitro studies have demonstrated that FLT3 inhibitor, CEP-701, 
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effectively suppresses FLT3 driven leukemic cell survival (Brown et al., 2006; Brown et al., 
2005). 
Monoclonal antibodies, including rituximab (anti-CD20), epratuzumab (anti-CD22), 
inotuzumab (anti-CD22), recombinant immunotoxins and bispecific antibodies 
(blinatumomab) and radioimmunotherapy have already been incorporated into clinical 
trials or are undergoing investigation. (Attias and Weitzman, 2008; Christiansen and  
Rajasekaran, 2004; Dworzak et al., 2008; Oriuchi et al., 2005; Reichert and Valge- Archer, 
2007; Topp et al., 2011) 
The application of emerging DNA and RNA techniques, SNP arrays, DNA methylation 
arrays and genome-wide association studies has led to the discovery of further genetic and 
epigenetic alterations. IKZF1, JAK mutations, and CDKN2A/B are among several examples 
which have been shown to be related to leukemogenesis and drug resistance (Davidsson et 
al., 2009; Yang et al., 2009; Yu et al., 2011). MicroRNAs alterations and dysregulation of 
DNA methylation have also been found in children with ALL and are being assessed as new 
targets for treatment (Bachmann et al., 2010; Davidsson et al., 2009; Herman et al., 1996; 
Schotte et al., 2011). In the near future, more individualized treatment strategies will be 
established based on detailed genetic and epigenetic characteristics, response to early 
treatment and MRD monitoring Such strategies will require precise supportive care. 
7. Supportive care  
7.1 Tumor lysis syndrome 
Tumor lysis syndrome (TLS) is a well-recognized complication of leukemia and lymphoma, 
especially in patients with B-cell or T-cell neoplasms and a large tumor burden (Alperin and 
Levin, 1964; Cohen et al., 1980; Jones, D.P. et al., 1990; Kedar et al., 1995; Kuhbock et al., 
1968; Rieselbach et al., 1964). TLS may occur spontaneously or during the early phase of 
treatment and can lead to severe metabolic disturbances (hyperuricemia, 
hyperphosphatemia, hyperkalemia, and hypocalcemia) (Jones, D.P. et al., 1995). TLS-
associated hyperuricemia may cause acute renal failure because of the rapid and dramatic 
increase of uricemia and renal burden of uric acid urate. Without appropriate management, 
precipitation of uric acid crystals can obstruct the tubules and collecting ducts, resulting in 
tubular necrosis and renal failure (Renyi et al., 2007). Allopurinol, which is an inhibitor of 
the enzyme xanthine oxidase, combined with hydration, osmotic diuretics and urinary 
alkalization has been the standard treatment for TLS since the late 1960s and remains an 
important part of leukemia treatment (Aviles, 1995; DeConti and Calabresi, 1966; Holland 
and Holland, 1968; Jones, D.P. et al., 1995; Rundles, 1966; Watts, 1966). Through blocking 
uric acid formation, allopurinol can effectively lower the serum uric acid level, but it 
increases the renal load of hypoxanthine and xanthine (both are uric acid precursors) 
(Andreoli et al., 1986; DeConti and Calabresi, 1966). Allopurinol treatment has been 
associated with xanthine nephropathy and calculi because xanthine is actually less soluble 
than uric acid in urine (Band et al., 1970; Wyngaarden, 1970). Moreover, allopurinol may 
interact with chemotherapy agents and affect drug metabolite concentrations (Rundles, 
1966).  
Urate oxidase, an endogenous enzyme in most mammals but not in humans, can act as a 
catalyst in the oxidation of uric acid to allantoin. Because allantoin is five to ten-fold more 
soluble than uric acid, urate oxidase can effectively decrease uric acid levels in patients with 
TLS (Brogard et al., 1972). Recombinant urate oxidase was introduced in France in 1975. 
During the 1980s and 1990s, non-recombinant urate oxidase (Uricozyme; Sanofi-Synthelabo, 
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Inc, Paris), purified from cultures of Aspergillus flavus, was used in the treatment of TLS in 
ALL patients (Masera et al., 1982). Although it improved the elimination of uric acid, 
however, this agent was found to be associated with allergic reactions (rashes, 
bronchospasm , urticaria and angioedema) in about 5% of patients, even in those without a 
history of allergy (Patte et al., 2001; Pui, C.H. et al., 1997). A new urate oxidase (rasburicase) 
was developed by use of a recombinant DNA technique in 1996 (Cammalleri and 
Malaguarnera, 2007). This approach allowed more rapid production of greater quantities of 
urate oxidase. Rasburicase is purer than non-recombinant urate oxidase, has greater activity 
and lower allergic reaction rates. Studies of the use of rasburicase in patients with ALL, have 
shown it to be a safe and effective alternative to allopurinol for the prevention and treatment 
of hyperuricemia (Cammalleri and Malaguarnera, 2007; Cheson and Dutcher, 2005; Lee et 
al., 2003; McNutt et al., 2006; Patte et al., 2001; Pui, C.H., 2001; Sood et al., 2006; Wang et al., 
2006). The toxicity of rasburicase is negligible, although the presence of anti-rasburicase 
antibodies has been reported in some patients (Pui, C.-H. et al., 2001).     
7.2 Infections 
Neutropenia is usually found when ALL is newly diagnosed or during chemotherapy, 
especially induction therapy. Children with ALL and disease-induced or treatment-related 
neutropenia, (usually defined as absolute neutrophil count less than 500 per mm3) are more 
prone to severe bacterial, fungal and viral infections (Freifeld et al., 2011). More febrile 
neutropenia episodes occur during induction of remission than during remission in children 
with ALL. The risk of severe infection is high with severe neutropenia (less than 200 per 
mm3)(Jones, G.R. et al., 1996; Peng et al., 1981). Both the degree and duration of neutropenia 
affect the risk of infection. For the purpose of managing febrile neutropenia, patients have 
been categorized into different risk groups. Rackoff et al. classified patients with febrile 
neutropenia into three risk groups based on the absolute monocyte count and temperature 
at the time of admission.  They found that the odds ratio of bacteremia for the high-risk 
versus the intermediate-risk group is 4.4 (no bacteremia episodes were found in the low-risk 
group)(Rackoff et al., 1996). The Infectious Disease Society of America (IDSA) started 
categorizing patients with febrile neutropenia in 2002 and the updated recommendation 
published in 2010 divided these patients into high-risk or low-risk groups according to the 
presenting symptoms and signs, neutrophil counts, underlying cancer, type of therapy, the 
anticipated length of neutropenia and medical comorbidities. The high-risk group was 
defined when any of the following criteria applied : profound neutropenia anticipated for 
longer than 7 days, evidence of hepatic or renal insufficiency, comorbidities with unstable 
vital signs, severe mucositis, gastrointestinal symptoms, neurological symptoms, catheter-
related infections, new pulmonary infiltration or hypoxia (Freifeld et al., 2011). It was 
suggested that high-risk patients be admitted at once and that antibiotics should be 
administered on an empirical basis as soon as possible. Worldwide, the etiology of 
infections is now predominantly due to Gram-positive bacterial pathogens. In a study 
conducted in 1981, Gram-positive and Gram-negative bacteria were equally represented 
(Peng et al., 1981). In another study, Gram-negative bacteria accounted for the great majority 
of the etiologic agents (Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa were 
the three most common pathogens) (Bodey et al., 1978). Recent studies have showed that 
Gram-positive bacteria account for more than fifty percent of bacterial episodes with 
coagulase-negative staphylococci, viridans streptococci and Staphylococcus aureus being 
the most common pathogens (Hakim et al., 2009).  
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Systemic (invasive) fungal infections are another common infection in patients with febrile 
neutropenia. ALL was the second most common underlying disease associated with proven 
invasive fungal infections after acute myelogenous leukemia in children treated for cancers 
(Mor et al., 2011). In earlier studies, systemic fungal infections occurred in around 20% of 
cases of pediatric acute leukemia during induction chemotherapy and the duration of 
neutropenia was a significant risk factor (Wiley et al., 1990). In the late 1990s, when 
antifungal prophylaxis and early initiation of empirical antifungal therapy were introduced, 
the rate of invasive fungal infections decreased, although the rate of fungal colonization in 
children receiving remission induction therapy for acute leukemia was still high 
(Gozdasoglu et al., 1999). In a study conducted in 2007, the occurrence of invasive fungal 
infections was monitored after renovation of the ventilation system on a pediatric 
hematology/oncology unit and initiation of routine azole antifungal prophylaxis. The 
incidence of proven invasive fungal infection was 3.2% (1/31) in the allogenic stem cell 
transplant group, 0/26 in autologous stem cell transplant group and 1.6%(1/60) in the 
induction therapy group (Hovi et al., 2007). In 2010, IDSA guidelines proposed antifungal 
prophylaxis administration in high-risk groups, and empiric antifungal therapy or 
preemptive therapy in patients with febrile neutropenia 4-7 days after broad-spectrum 
antibiotics treatment (Freifeld et al., 2011). However, a shift of fungal pathogens from 
Candida sp. towards mold infections was observed along with the increasing use of 
antifungal prophylaxis. In a recent study which enrolled 1047 children with different 
malignancies, 20% of the proven invasive fungal infections had candidemia and 80% had 
mold infections. Non-albicans candida accounted for 60% of all candidemia and 55% of 
mold infections were non-Aspergillus (Mor et al., 2011). Although the incidence of and 
mortality due to invasive fungal infections were both lower than previously reported, the 
epidemiologic spectrum of fungus isolates has broadened and this should be considered in 
the selection of antifungal agents for prophylaxis or empirical treatment. 
Granulocyte-colony stimulation factor (G-CSF) or granulocyte-monocyte colony stimulating 
factor (GM-CSF) have the potential benefits of reducing the duration of neutropenia and, in 
turn, the risk of infection. A meta-analysis of 16 randomized controlled trials concluded that 
prophylactic use of G-CSF or GM-CSF was associated with a 20% reduction in febrile 
neutropenia and a two-day decrease in duration of hospitalizations (Sung et al., 2004). IDSA 
2010 guidelines recommend prophylactic use of G-CSF or GM-CSF for patients in whom the 
predicted risk of fever and neutropenia is over 20% (Freifeld et al., 2011).   
8. Conclusion 
Pediatric ALL is the most common malignancy in children. The cure rates of pediatric ALL 
have improved greatly through use of risk-adapted therapy and aggressive supportive care. 
Advances in molecular biology and high-throughput technology will allow further 
investigation of the mechanisms of leukemogenesis and disease relapse and will, in turn, 
lead to more sophisticated treatments in the future.    
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